|Day Low/High||0.50 / 0.55|
|52 Wk Low/High||0.10 / 1.74|
With the state of Oregon's move to decriminalize drugs, the stigma around compounds like ketamine is lessening.
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.
Investors are anxious to grab the next penny stock that may be poised to jump on the mind-blowing bubble. Here they are.
As crisis turns into one of mental health as well as physical health, some firms are experimenting with use of LSD and 'magic mushroom' compounds.